AI-Enabled Digital Stethoscope
Point-of-care AI predictions for left ventricular systolic dysfunction
Device · EmbeddedCompany source
Company profile
About Anumana AI
Anumana is an AI-driven health technology company developing ECG algorithms enabling early diagnosis and intervention for cardiovascular diseases.
Company description Anumana AI official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Work at Anumana AI?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Atrial fibrillation
- Cardiac amyloidosis
- Cardiomyopathies
- Heart failure
- Hyperkalemia
- Left ventricular diastolic dysfunction
- Low ejection fraction
- Peripartum cardiomyopathy
- Pulmonary hypertension
Who it serves
- Cardiology practices
- Clinics
- Health Systems
- Hospitals
Deployment & integration
Embedded · On Premise · Other deployment with recorded integration context.
Recorded integration context: Compatible with many ECG systems commonly used in clinical practice, ECG Management Systems (XML or DICOM waveform files), EHR systems via HL7 integration.
Geographic context
MarketsEuropean Union · Nigeria · United States
Company sourceOfficial website
Company milestones
Platform expansion
FDA clearance for ECG-AI Cardiac Amyloidosis algorithm (April 2026 - first and only). Expanding into perioperative cardiac care with generative AI imaging technologies. Multiple peer-reviewed publications in 2024-2026 including Nature Medicine, JACC, European Heart Journal.
Partnerships
Recorded partners
- 6 hospitals in Nigeria (SPEC-AI trial)
- Leading academic medical centers (exclusive partnerships for 22M+ patient records)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
ECG-AI Platform
Secure, clinically validated infrastructure for seamless ECG-AI integration
Platform · On PremiseCompany source
ECG-AI Pulmonary Hypertension
AI algorithm for pulmonary hypertension detection from ECG
Software · On PremiseCompany source
ECG-AI® Cardiac Amyloidosis
First and only FDA-cleared ECG-AI algorithm for cardiac amyloidosis detection
Software · On PremiseCompany source
ECG-AI® Cardiac Amyloidosis Algorithm
First and only FDA-cleared ECG-AI algorithm for cardiac amyloidosis detection
Software · On PremiseCompany source
ECG-AI® LEF
AI-powered detection of low left ventricular ejection fraction from standard 12-lead ECG
Software · On PremiseCompany source
ECG-AI® Pulmonary Hypertension Algorithm
First-of-its-kind ECG-AI algorithm for early detection of pulmonary hypertension
Software · On PremiseCompany source
Perioperative Cardiac Imaging Platform
Real-time AI imaging and visualization for cardiac interventions
Platform · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
4.1% vs 2.0% detection rate
LVSD detection in obstetric population using AI-guided screening vs usual care (OR 2.12, P=0.032)
Early identification of at-risk patients
Detection of cardiac disease signals invisible to human eye from standard ECGs
Eligible for reimbursement
CPT III codes configured for charge capture
Philips ECG Ecosystem
Integration of Anumana's FDA-cleared LEF algorithm as first certified third-party solution through Philips' ECG-AI Marketplace to enhance early cardiac diagnosis
First certified third-party solution available through Philips' ECG ecosystem
6 hospitals in Nigeria
AI-guided screening for cardiomyopathies in pregnant and postpartum women in Nigeria, which has the highest reported incidence of peripartum cardiomyopathy worldwide
4.1% detection rate vs 2.0% in control group (2.12x odds ratio, P=0.032) - detected 24 out of 587 patients with LVSD using AI-enabled digital stethoscope compared to 12 out of 608 in standard care
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Anumana AI
Recent articles published on Anumana AI's official website.
The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption
Read on Anumana AISupporting Predictive Analytics to Improve Clinical Decision Making and Patient Outcomes
Read on Anumana AIAnumana Makes Educated Inferences in Heart Failure
Read on Anumana AIBridging ECG Signals and EHR data through Contrastive Learning
Read on Anumana AIAnumana Appoints Kevin Ballinger and Jean-Luc Butel to Board of Directors
Read on Anumana AI07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.